Nico Sollmann1,2,3, Tobias Laub1, Anna Kelm1, Lucia Albers4, Jan S Kirschke3, Stephanie E Combs5,6, Bernhard Meyer1, Sandro M Krieg1,2. 1. Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Germany. 2. TUM-Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Germany. 3. Section of Neuroradiology, Department of Radiology, Klinikum rechts der Isar, Technische Universität München, Germany. 4. Institute of Social Pediatrics and Adolescents Medicine, Ludwig-Maximilians-Universität München, Germany. 5. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Germany. 6. Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Germany.
Abstract
BACKGROUND: Due to frequent recurrences, high-grade gliomas still confer a poor prognosis. Several regrowth prediction models have been developed, but most of these models are based on cellular models or dynamic mathematical calculations, thus limiting direct clinical use. The present study aims to evaluate whether navigated transcranial magnetic stimulation (nTMS) or functional magnetic resonance imaging (fMRI) may be used to predict the direction of tumor regrowth. METHODS: Sixty consecutive patients with high-grade gliomas were enrolled prospectively and analyzed in a case-control design after tumor recurrence. All patients underwent serial MRI after surgery and suffered from recurrent tumors during a mean follow-up of 13.2 ± 14.9 months. Tumor regrowth speed and direction were measured in relation to motor areas defined by nTMS, nTMS-based tractography, and fMRI. Depending on initial resection, patients were separated into three groups (group 1: without residual tumor, group 2: residual tumor away from motor areas, and group 3: residual tumor facing motor areas). RESULTS: Sixty-nine percent of patients in group 1, 64.3% in group 2, and 66.7% in group 3 showed tumor recurrence towards motor eloquence on contrast-enhanced T1-weighted sequences (P = .9527). Average growth towards motor areas on contrast-enhanced T1-weighted sequences was 0.6 ± 1.5 (group 1), 0.6 ± 2.4 (group 2), and 2.3 ± 5.5 (group 3) mm/month (P = .0492). CONCLUSION: This study suggests a new strategy to predict tumor regrowth patterns in high-grade glioma patients. Our approach could be directly applied in the clinical setting, thus having clinical impact on both surgical treatment and radiotherapy planning. ETHICS COMMITTEE REGISTRATION NUMBER: 2793/10.
BACKGROUND: Due to frequent recurrences, high-grade gliomas still confer a poor prognosis. Several regrowth prediction models have been developed, but most of these models are based on cellular models or dynamic mathematical calculations, thus limiting direct clinical use. The present study aims to evaluate whether navigated transcranial magnetic stimulation (nTMS) or functional magnetic resonance imaging (fMRI) may be used to predict the direction of tumor regrowth. METHODS: Sixty consecutive patients with high-grade gliomas were enrolled prospectively and analyzed in a case-control design after tumor recurrence. All patients underwent serial MRI after surgery and suffered from recurrent tumors during a mean follow-up of 13.2 ± 14.9 months. Tumor regrowth speed and direction were measured in relation to motor areas defined by nTMS, nTMS-based tractography, and fMRI. Depending on initial resection, patients were separated into three groups (group 1: without residual tumor, group 2: residual tumor away from motor areas, and group 3: residual tumor facing motor areas). RESULTS: Sixty-nine percent of patients in group 1, 64.3% in group 2, and 66.7% in group 3 showed tumor recurrence towards motor eloquence on contrast-enhanced T1-weighted sequences (P = .9527). Average growth towards motor areas on contrast-enhanced T1-weighted sequences was 0.6 ± 1.5 (group 1), 0.6 ± 2.4 (group 2), and 2.3 ± 5.5 (group 3) mm/month (P = .0492). CONCLUSION: This study suggests a new strategy to predict tumor regrowth patterns in high-grade glioma patients. Our approach could be directly applied in the clinical setting, thus having clinical impact on both surgical treatment and radiotherapy planning. ETHICS COMMITTEE REGISTRATION NUMBER: 2793/10.
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Stephanie E Combs; Johanna Wagner; Marc Bischof; Thomas Welzel; Florian Wagner; Jürgen Debus; Daniela Schulz-Ertner Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-29 Impact factor: 7.038
Authors: Daniel J Brat; Amilcar A Castellano-Sanchez; Stephen B Hunter; Marcia Pecot; Cynthia Cohen; Elizabeth H Hammond; Sarojini N Devi; Balveen Kaur; Erwin G Van Meir Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701